Cantor Fitzgerald has a convertible bond with Tether, incoming Commerce Secretary Howard Lutnick said at his confirmation hearing, confirming previous reporting by The Wall Street Journal that

Cantor Fitzgerald upgraded shares of Zevra Therapeutics (NASDAQ:ZVRA – Free Report) to a strong-buy rating in a research note issued to investors on Wednesday,Zacks.com reports. Other equities research analysts also recently issued research reports about the company.

Cantor Fitzgerald reiterated a Neutral rating on Intel Corporation (NASDAQ:INTC) with a consistent price target of $22.00. According to InvestingPro analysis, Intel appears slightly undervalued at its current market cap of $86.

“As you can imagine, the pain we suffered with Gary and 657 of my other friends and colleagues at Cantor Fitzgerald were killed on 9/11,” Lutnick said during his confirmation hearing before ...

This month, Flagstar offloaded $142 million of that portfolio, finding a buyer in Howard Lutnick’s Cantor Fitzgerald, PincusCo reported. A spokesperson for Cantor Fitzgerald did not return a ...

Cantor Fitzgerald currently has a “Overweight” rating and a $44.00 price objective on the stock. The consensus estimate for Sanara MedTech’s current full-year earnings is ($1.33) per share.

Cantor Fitzgerald upgraded Lam Research (LRCX) to Overweight from Neutral with a price target of $100, up from $95. The firm had suggested

Meanwhile, his firm, Cantor Fitzgerald has a significant presence in Ireland, with offices in Cork, Dublin and Limerick Howard Lutnick, chairman and chief executive officer of Cantor Fitzgerald ...

Cantor Fitzgerald raised the firm’s price target on Tesla (TSLA) to $425 from $365 and keeps a Neutral rating on the shares. Tesla’s adjusted

Donald Trump's commerce secretary nominee told his US Senate confirmation hearing Wednesday he favors "across-the-board" tariffs targeting countries rather than products, while signaling a hawkish China stance.

Fintel reports that on January 31, 2025, Cantor Fitzgerald initiated coverage of Acrivon Therapeutics (NasdaqGM:ACRV) with a Overweight recommendation. Analyst Price Forecast Suggests 260.44% Upside As of January 29,

Cantor Fitzgerald analyst Sarah James maintained a Buy rating on Cigna (CI – Research Report) yesterday and set a price target of $350.00. The